GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Terns Pharmaceuticals Inc (NAS:TERN) » Definitions » Interest Coverage

TERN (Terns Pharmaceuticals) Interest Coverage : N/A (As of Sep. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Terns Pharmaceuticals Interest Coverage?

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income by its Interest Expense. Terns Pharmaceuticals's Operating Income for the three months ended in Sep. 2024 was $-24.94 Mil. Terns Pharmaceuticals's Interest Expense for the three months ended in Sep. 2024 was $0.00 Mil. GuruFocus does not calculate 's interest coverage with the available data. The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Ben Graham prefers companies' interest coverage to be at least 5. Terns Pharmaceuticals Inc has enough cash to cover all of its debt. Its financial situation is stable.

(1) Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

The historical rank and industry rank for Terns Pharmaceuticals's Interest Coverage or its related term are showing as below:


TERN's Interest Coverage is not ranked *
in the Biotechnology industry.
Industry Median: 137.08
* Ranked among companies with meaningful Interest Coverage only.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.


Terns Pharmaceuticals Interest Coverage Historical Data

The historical data trend for Terns Pharmaceuticals's Interest Coverage can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Terns Pharmaceuticals Interest Coverage Chart

Terns Pharmaceuticals Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Interest Coverage
Get a 7-Day Free Trial No Debt No Debt No Debt N/A No Debt

Terns Pharmaceuticals Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Interest Coverage Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only N/A No Debt No Debt No Debt N/A

Competitive Comparison of Terns Pharmaceuticals's Interest Coverage

For the Biotechnology subindustry, Terns Pharmaceuticals's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Terns Pharmaceuticals's Interest Coverage Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Terns Pharmaceuticals's Interest Coverage distribution charts can be found below:

* The bar in red indicates where Terns Pharmaceuticals's Interest Coverage falls into.



Terns Pharmaceuticals Interest Coverage Calculation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:

If Interest Expense is negative and Operating Income is positive, then

Interest Coverage=-1* Operating Income /Interest Expense

Else if Interest Expense is negative and Operating Income is negative, then

The company did not have earnings to cover the interest expense.

Else if Interest Expense is 0 and Long-Term Debt & Capital Lease Obligation is 0, then

The company had no debt (1).


Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Terns Pharmaceuticals's Interest Coverage for the fiscal year that ended in Dec. 2023 is calculated as

Here, for the fiscal year that ended in Dec. 2023, Terns Pharmaceuticals's Interest Expense was $0.00 Mil. Its Operating Income was $-102.56 Mil. And its Long-Term Debt & Capital Lease Obligation was $0.00 Mil.

Terns Pharmaceuticals had no debt (1).

Terns Pharmaceuticals's Interest Coverage for the quarter that ended in Sep. 2024 is calculated as

Here, for the three months ended in Sep. 2024, Terns Pharmaceuticals's Interest Expense was $0.00 Mil. Its Operating Income was $-24.94 Mil. And its Long-Term Debt & Capital Lease Obligation was $1.03 Mil.

GuruFocus does not calculate Terns Pharmaceuticals's interest coverage with the available data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's Financial Strength is.


Terns Pharmaceuticals  (NAS:TERN) Interest Coverage Explanation

Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.

Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .


Terns Pharmaceuticals Interest Coverage Related Terms

Thank you for viewing the detailed overview of Terns Pharmaceuticals's Interest Coverage provided by GuruFocus.com. Please click on the following links to see related term pages.


Terns Pharmaceuticals Business Description

Traded in Other Exchanges
Address
1065 East Hillsdale Boulevard, Suite 100, Foster, CA, USA, 94404
Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, NASH, and other chronic liver diseases.
Executives
Hongbo Lu director C/O AVEDRO, INC., 201 JONES ROAD, WALTHAM MA 02451
Mark J. Vignola officer: Chief Financial Officer C/O APPLIED THERAPEUTICS, INC., 340 MADISON AVENUE, 19TH FLOOR, NEW YORK NY 10173
Jill M. Quigley director TWO COMMERCE SQUARE, 2001 MARKET STREET, 28TH FLOOR, PHILADELPHIA PA 19103
Orbimed Advisors Llc director, 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Carl L Gordon director, 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Seokho Bryan Yoon officer: COO and General Counsel NIGHTSTAR THERAPEUTICS PLC, 203 CRESCENT STREET, SUITE 303, WALTHAM MA 02453
Vivo Opportunity Fund Holdings, L.p. 10 percent owner 192 LYTTON AVENUE, PALO ALTO CA 94301
Senthil Vel Sundaram director, officer: Chief Executive Officer NIGHTSTAR THERAPEUTICS PLC, 203 CRESCENT STREET, SUITE 303, WALTHAM MA 02453
Oriental Spring Venture Ltd 10 percent owner UNIT 902-904, TWO CHINACHEM CENTRAL, 26 DES VOEUX ROAD CENTRAL K3 000000
Lav Biosciences Fund V, L.p. 10 percent owner C/O ESTERA TRUST (CAYMAN) LIMITED, 75 FORT STREET, PO BOX 1350, GRAND CAYMAN E9 KY1-1108
Hopewell Resources Holdings Ltd 10 percent owner UNIT 902-904, TWO CHINACHEM CENTRAL, 26 DES VOEUX ROAD CENTRAL K3 000000
Lav Aqua Ltd 10 percent owner UNIT 902-904, TWO CHINACHEM CENTRAL, 26 DES VOEUX ROAD CENTRAL K3 000000
Orbimed Genesis Gp Llc director, 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Orbimed Capital Gp Vii Llc director, 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022
Orbimed Advisors Iii Ltd director, 10 percent owner 601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022-4629